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Conformationally-Locked C-Glycosides: Tuning 
Aglycone Interactions for Optimal Cheperone 
Behaviour in Gaucher Fibroblasts 
C. D. Navo,a F. Corzana,a E. M. Sánchez-Fernández,b J. H. Busto,a A. Avenoza,a 
E. Namba,c K. Higaki,c C. Ortiz Mellet,b* J. M. García Fernándezd* and J. M. 
Peregrinaa* 
A series of conformationally locked C-glycosides based on the 3-aminopyrano[3,2-b]pyrrol-
2(1H)-one (APP) scaffold has been synthesized. The key step involved a totally 
stereocontrolled C-Michael addition of a serine-equivalent C-nucleophile to tri-O-benzyl-2-
nitro-D-galactal. Stereoselective transformations of the corresponding Michael adduct 
allowed us the synthesis of compounds with mono- or diantennated aglycone moieties and 
different topologies. In vitro screening showed highly selective inhibition of bovine liver β-
glucosidase/-galactosidase and specific inhibition of human -glucocerebrosidase among 
lysosomal glycosidases for compounds bearing palmitoyl chains in the aglycone, with a 
marked dependence of the inhibition potency upon their number and location. Molecular 
dynamics simulations highlighted the paramount importance of an optimal orientation of the 
hydrophobic substituent to warrant efficient non-glycone interactions, which are critical for 
the binding affinity. The results further provide a rational for the strong decrease of the 
inhibiton potency of APP compounds on going from neutral to acidic pH. The best candidate 
was found to behave as a chaperone in Gacuehr fibroblasts with homozygous N370S and 
F213I mutations, with enzyme activity enhancements similar to those encountered for the 
reference compound Ambroxol®.  
 
Introduction 
Glycosidases are enzymes that catalyze the hydrolysis of 
glycosidic bonds, thereby playing a key role in biochemical 
routes that are essential for life such as the processing of 
glycoproteins and the catabolism of polysaccharides and 
glycoconjugates. Deregulation of any of these enzymes 
generally translates into significant biological and pathological 
consequences, which has fuelled research in compounds 
interfering with their activity as potential drug candidates.1 The 
carbohydrate mimics (glycomimetics) of the iminosugar type, 
such as the piperidine derivative 1-deoxynojirimicyn (DNJ) or 
the indolizidine analogue castanospermine (CS, Figure 1), 
represent by far the most studied family of molecules towards 
these channels.2 Their polyhydroxylated structure emulates that 
of the natural monosaccharides, enabling them to compete with 
the substrate for the glycone pocket in the active site of 
glycosidases, behaving as competitive inhibitors..However, 
classical iminosugars cannot fully reproduce the structure of the 
putative glycoside substrates due to the instability of 
aminoacetal functional groups, which often translates into poor 
selectivity. Even though rigidification of the azaheterocyclic 
core in bicyclic derivatives can be exploited to improve the 
discrimination capacity between isoenzymes, the absence of a 
defined anomeric configuration generally results in 
simultaneous inhibition of glycosidases acting on anomeric 
substrates, i.e. - and -glucosidases in the case of DNJ and 
CS, which represents a serious handicap for clinical 
applications.3 
The urgent need for more specific glycosidase inhibitors has 
fuelled research on synthetic glycomimetics targeting medically 
relevant enzymes.4,5. In principle, molecular prototypes 
mirroring the full structure of glycosides, that is incorporating 
both glycone- and aglycone-like portions and benefiting from a 
defined pseudoanomeric configuration, are better suited for that 
purpose.6 For example, sp2-iminosugar cores,7 in which the 
endocyclic nitrogen is part of a pseudoamide functionality, are 
compatible with the incorporation of axially-oriented 
pseudoanomeric substituents through stable O-, S- or N-
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glycosidic linkages (Figure 1), which has been exploited in the 
design of specific -glucosidase inhibitors exhibiting anticancer 
ad antileishmanial activities.8 N-alkylated bicyclic isoureas 
derived from aminocyclitol scaffolds (e.g., 
benzo[d]oxazolimine derivatives, Figure 1) behaved instead as 
very selective inhibitors of human lysosomal -glucosidase, 
exhibiting strong pharmacological chaperone potential for the 
treatment of Gaucher disease.9 Interestingly, some examples of 
glycosidase inhibitors keeping the pyranose ring as the glycone 
constituent have also been reported, which presents advantages 
in term of synthetic procedures. An example is thiamet G 
(Figure 1), a fused pyranose-thiazoline derivative, that acts as a 
potent inhibitor of O-linked 2-acetamino-2-deoxy-β-D-
glucopyranoside hydrolysis currently in preclinical evaluation 
as a potential therapeutic for the treatment of Alzheimer’s 
disease.10 The conformationally-locked bicyclic N-glycoside 
derivatives of the pyranose-sulfanyl-1,3-oxazoline family 
(PSO, Figure 1) exhibit β-glucosidase inhibitory activity that is 
strongly dependent on the nature of the psudoaglycone S-
substituent, some representatives behaving as pharmacological 
chaperones for Gaucher disease.11 
Figure 1. Some iminosugars and bicyclic derivatives glycosidase 
inhibitors. 
The pyrano[3,2-b]pyrrole framework (Figure 1) has also been 
suggested as a suitable scaffold for the preparation of 
glycosidase inhibitors.12 The lack of effective synthetic 
methods compatible with the incorporation of aglycone-type 
susbtituents has burdened optimization of the affinity and 
selectivity towards biomedically relevant enzyme targets, 
however.13 The development of efficient approaches towards 
this framework through synthetic routes compatible with 
structurally diversity-oriented strategy is therefore highly 
wanted. The possibility of accessing conformationally-
restricted multiantennated derivatives with C-glycoside 
structure is particularly appealing14 given that many medically 
relevant glycosidases, such as those that are dysfunctional in 
glycosphingolipid-related metabolic disorders, act on substrates 
with branched aglycone segments.15 
With this background, we have now envisioned the synthesis of 
3-amino-6,7-dihydroxy-3,5-
bis(hydroxymethyl)hexahydropyrano[3,2-b]pyrrol-2(1H)-one 
derivatives (APP, Figure 1) as a new family of non-iminosugar-
type glycosidase inhibitors. The disubstitution pattern at the 
exocyclic quaternary anomeric carbon, which bears 
simultaneously a hydroxymethyl and an amino group 
susceptible of chemical modification, offer broad opportunities 
for the incorporation of non-glycone moieties. The  
optimization of the synthesis of a key synthetic precursor for 
APP synthesis, the subsequent transformation into a broad 
battery of mono- and diantennated APP derivatives and the 
assessment of the affinity and selectivity of the final 
compounds against a panel of commercial and human 
glycosidase enzymes is presented. 
 
Results and discussion 
Recently, a totally stereocontrolled C-Michael addition of a 
serine-equivalent C-nucleophile to tri-O-benzyl-2-nitro-D-
galactal (nitrogalactal) was used as the key step to synthesize 
several pyrano[3,2-b]pyrrole structures, e.g. compound 1, 
following reduction of the nitro group in the corresponding 
Michael adduct.16 Interestingly, spirocycle 1 can be regarded as 
a protected form of the target APP derivatives (Scheme 1). To 
explore this channel, an optimized preparation of 1 in gram 
scale was a prerequisite. This goal was conveniently achieved 
by using platinized Raney Ni under an atmosphere of 
hydrogen17 in the reduction step. The transient amino group 
reacted spontaneously with the methyl ester group to close the 
corresponding five-membered lactam ring with retention of the 
configuration at both stereocenters. 
 
Scheme 1. Retrosynthetic analysis of APP derivatives. 
Compound 1 was next used as a precursor for the synthesis of a 
battery of APP derivatives. In a first step, concomitant 
hydrolysis of the acetal and cyclic carbamate groups, by 
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treatment with 4 M aqueous HCl at 40 °C for 12 h and liberation 
of the resulting ammonium hydrochloride salt by the action of 
propylene oxide in ethanol at reflux, provided aminoalcohol 2 
in excellent yield (96%). Acylation of 2 with palmitoyl chloride 
in the presence of trimethylamine at room temperature for 12 h 
afforded the diantennated derivative 3 (70% yield), which was 
subsequently  de-O-benzylated by hydrogenolysis in acidified 
methanol, using palladium on carbon as a catalyst ,to give the 
unprotected APP 4 in only three steps and 62% overall yield 
(Scheme 2). 
 
 
Scheme 2. Synthesis of target compounds 4, 6, 8 and 11 incorporating palmitoyl subtituents. 
Compound 3 was also selectively de-O-acylated with sodium 
methoxide in methanol at pH 9 to give the corresponding 
alcohol 5, which after debenzylation following the above 
procedure afforded the corresponding APP derivative 6, bearing 
a single-chain N-palmitoyl aglycone moiety (Scheme 2). The 
homologous O-palmitoyl monantennated adduct 8, keeping a 
free amino group in the aglycone, was obtained from the 
pivotal precursor 1 after acid hydrolysis, in situ regioselective 
O-acylation with palmitoyl chloride, neutralization with 
propylene oxide in ethanol and hydrogenolysis of the tribenzyl 
ether 7 (62% overall yield; Scheme 2). The possibility of 
conducting chemoselective acylation of the masked hydroxy 
and amino groups in 1 is further compatible with the 
incorporation of different substituent at each position. Thus,  
palmitoylation of the previously reported N-acetylated 
compound 916 followed by hydrogenolysis of the resulting ester 
10 led to the new APP derivative 11 (Scheme 2). Finally, 
compounds 13-15, featuring O-acetyl and a free amino groups, 
free hydroxyl and amino groups, or free hydroxy and N-acetyl 
groups in the aglycone segment, respectively were prepared as 
controls to assess the influence of the presence of the long 
hydrophobic segments in the glycosidase inhibitory properties 
of the PAA (Scheme 3). 
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Scheme 3. Synthesis of target compounds 13-15 without large alkyl 
chains. 
Compounds 4, 6, 8, 11, 13, 14 and 15 were first evaluated 
against a panel of commercially available glycosidase enzymes 
including -glucosidase (baker yeast), isomaltase (baker yeast), 
amyloglucosidase (A. niger), -glucosidase/-galactosidase 
(bovine liver), -galactosidase (E. coli), -galactosidase (green 
coffee), -glucosidase (almonds), -mannosidase (Jack bean), 
-mannosidase (H. pomatia) and -N-acetylglucosaminidase 
(human placenta, bovine kidney and Jack bean). Inhibition 
constants (Ki, M) were determined from the slope of 
Lineweaver-Burk plots (see Figure 2 for a representative 
example) and are collected in Table 1. The data confirm that the 
presence of a hydrophobic segment in the aglycone (4, 6, 8 and 
11) is necessary to elicit a significant activity, isomaltase (Ki, 
13-80 M) and -glucosidase/-galactosidase (Ki, 5.8-86 M) 
being the more sensitive enzymes to APP inhibition. The 
presence of a bulky substituent at the nitrogen atom (4 and 6) is 
detrimental for isomaltase inhibition, whereas it has the 
opposite effect in the case of the mammalian -glucosidase/-
galactosidase enzyme. Compound 8, keeping a free amino 
group in the aglycone, additionally behaves as a M inhibitor of 
-glucosidase (Ki, 27 M) and -galactosidase (Ki, 67 M)  
 
 
Table 1. Glycosidase inhibitory activities (Ki, M) for APP derivatives against commercial glycosidases.[a] 
 
 [a] Inhibition, when detected, was competitive in all cases. No inhibition was detected for any of the compounds at concentrations up to 2 mM 
against amyloglucosidase (A. niger), -glucosidase (almonds), -galactosidase (E. coli), -mannosidase (Jack bean), -mannosidase (H. pomatia) 
and -N-acetylglucosaminidase (human placenta, bovine kidney and Jack bean). [b] Determined from the slope of Lineweaver_Burk Plots and 
Double Reciprocal Analysis. n.i. not inhibition detected at concentrations up to 2 mM. 
 
 
Inhibition of bovine liver β-glucosidase/-galactosidase has 
been often used as a preliminary parameter to select candidates 
as pharmacological chaperones for mutant forms of human β-
glucocerebrosidase (GCase) associated with Gaucher disease.18 
Although the predictive character of the data must be taken 
with care,19 the significant inhibitory potential and high 
selectivity encountered for some of the new APP compounds in 
Table 1 against the commercial enzyme warranted further 
evaluation in this sense. The concentrations of the di- (4) and 
monoantennated derivatives (6, 8 and 11) given 50% inhibition 
of human GCase are collected in Table 2. The corresponding 
data for the non-glycomimetic type pharmacological chaperone 
Ambroxol® (ABX), currently in preclinical studies for the 
treatment of Gaucher disease,20 are also included for 
comparative purposes. 
Enzymes 4 6 8 11 13 14 15 
-Glucosidase 
(Baker yeast) 
225±25 124±13 27±3 244±28  n.i. 532±58 n.i. 
Isomaltase 
(Baker yeast) 
80±9 34±4 13±1 19±2  97±11 283±31 n.i. 
-Glucosidase/-Galactosidase 
(Bovine liver) 
10±1[b]  5.8±0.6[b] 86±9 9.2±8[b]  n.i. n.i. n.i. 
-Galactosidase 
(Green coffee) 
657±72  515±56  67±7 n.i. n.i. n.i. n.i. 
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Figure 2. Lineweaver-Burk plot for Ki determination (5.8 M) of APP 
6 against -galactosidase (bovine liver) (pH 7.3). 
 
Table 2. IC50 values (M) against human GCase for APP 
derivatives 4, 6, 8 and 11. 
Compound GCase pH 7 GCase pH 5 
 
41±1 470±20 
 
23±1 272±10 
 
49±2 606±10 
 
67±5 707±20 
 
7.6±0.5 90±5 
 
The inhibition potency against GCase followed a slightly 
different trend as compared to that encountered for the 
commercial mammalian β-glucosidase/-galactosidase. The 
presence of the O-acyl substituent in the aglycone seems to be 
detrimental for the human enzyme. Thus, compound 6 (IC50 23 
M at pH 7), missing this group, is an about 2- to 3-fold 
stronger inhibitor than the three other APP derivatives assayed 
(IC50 41-67 M at pH 7), though it is still 3-fold weaker than 
the reference compound ABX (7.6 M). No inhibition of other 
lysosomal enzymes, such as -glucosidase, -galactosidase, -
galactosidase, and -hexosaminidase, was observed. Most 
interestingly, an about one-order-of-magnitude decrease in the 
GCase inhibition strength was observed at pH 5, a favorable 
feature for chaperone candidates.21   
The ensemble of data in Tables 1 and 2 highlight the paramount 
importance of non-glycone interactions in the affinity and 
selectivity towards glycosidases. They also underline the need 
for implementing strategies allowing structural modifications 
with a relatively low synthetic cost to optimize such 
interactions. The superiority of compound 6 as GCase inhibitor 
within the APP series is remarkable. To get further structural 
information, we performed 50 ns MD simulations22 on 6 in 
complex with the human enzyme (pdb code: 2WCG).23 The 
results support that the pyranoid glycone moiety is engaged in 
hydrogen bond networking in a similar manner to that 
previously encountered for other glycomimetic-type 
competitive inhibitors (Figure 3). Indeed, although the putative 
substrate of GCase is D-glucosylceramide, it has been shown 
that D-galacto configured glycomimetics do also fit well in the 
catalytic site. Noticeably, the calculations predict that the 
exocyclic amide nitrogen is involved in a hydrogen bond with 
the catalytic glutamic acid nucleophile Glu235. Protonation of 
this residue may be responsible for the large difference 
observed in the inhibitory potency of APP compounds at 
neutral and acidic pH. Moreover, this hydrogen bond orients 
the aliphatic N-substituent towards the hydrophobic region at 
the entrance of the active site of the enzyme, reinforcing the 
stability of the complex.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Representative frame obtained from the 50 ns MD simulation 
on human GCase:APP 6 complex showing the hydrogen bonds between 
the glycone unit of compound 6 and the residues in the binding site (left 
panel). The side chain of compound APP 6 is engaged in hydrophobic 
contacts with the surface of the enzyme (right panel). The hydrophobic 
residues of the enzyme are shown in orange.  
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All the four amphiphilic APP compounds were further assayed 
for their chaperoning capabilities using healthy and Gaucher 
fibroblasts from patients having the N370S/N370S, 
F213I/F213I or L444P/L444P GCase mutations. These variants 
are associated to the non-neuronopathic (type 1) and 
neuronopathic (types 2 and 3) phenotypes of Gaucher disease, 
respectively.24 Only the first one, with the highest prevalence 
and located in the catalytic domain of GCase, is responsive to 
the enzyme replacement or substrate reduction therapies 
currently available, The F213I/F213I mutation is also located in 
the catalytic domain of the enzyme, while the L444P/L444P 
mutation is located in a noncatalytic domain, which makes it 
less prone to rescuing by pharmacological chaperones.25 The 
cells were cultured for 5 days in the absence and in the presence 
of 2 or 20 M concentrations of the APP compounds, then 
lysed and the GCase activity determined using 4-
methylumbelliferyl -D-glucopyranoside as substrate. Enzyme 
activity variations relative to the control in the absence of any 
compound were thus monitored. Statistically significant activity 
enhancements were observed only for the N370S/N370S and 
F213I/F213I GCase mutants after treatment with compound 6 
at 20 M concentration, with relative increases of 1.3- and 1.5-
folds, respectively, which approach those achieved with the 
reference compound ABX (1.5- and 1.8-fold, respectively). 
None of the APP derivatives did exhibit toxic effect on any of 
the normal or mutant cell lines assayed for 5 days incubation. 
Conclusions 
In summary, we have devised an efficient methodology for the 
synthesis of conformationally locked C-glycosides based on the 
3-amino-3-hydroxymethylpyrano[3,2-b]pyrrol-2(1H)-one 
(APP) scaffold compatible with the incorporation of mono and 
multibranched aglycone moieties. Evaluation against a variety 
of glycosidase enzymes showed that amphiphilic derivatives 
bearing long hydrophobic substituents behaved as M 
competitive inhibitors of bovine liver -glucosidase/-
galactosidase. Most interestingly, they also behaved as selective 
inhibitors of human lysosomal -glucosidase (-
glucocerebrosidase) at neutral pH, with a remarkable decrease 
in the inhibitory potency upon acidification (pH 5). The pH 
dependency of glucocerebrosidase binding makes this type of 
compounds good candidates as pharmacological chaperones for 
Gaucher disease.  Indeed, compound 6, having a 
palmitoylamido segment in the aglycone, was able to increase 
the activity of N370S/N370S and F213I/F213I 
glucocerebrosidase mutants in fibroblasts of Gaucher patients 
with an efficiency similar to that of the reference compound 
Ambroxol®. MD simulations support the existence of a 
hydrogen bond involving the amide proton of the chaperone 
and the carboxylate group of the catalytic glutamic acid residue 
Glu235 thta favorably orients the palmitoyl chain towards a 
hydrophobic pocket in theenzyme. Since the protonation state 
of Glu235 changes in the pH 7-5, this structural feature offer 
further interesting opportunities for pH-dependent chaperone 
design. Research in that direction is currently sought in our 
laboratories.  
 
Experimental 
General Information 
Solvents were purified according to standard procedures. All 
reactions were followed by thin layer chromatography (TLC) 
where practical, using silica gel 60 F254 fluorescence treated 
silica gel plates, which were visualized under UV light (250 
nm). Column chromatography was performed using silica gel 
60 (230−400 mesh). 1H and 13C NMR spectra were recorded on 
a 400 MHz spectrometer using CDCl3, CD3OD, or D2O as the 
solvent; chemical shifts are reported in parts per million on the 
δ scale, and coupling constants are reported in Hertz. All of the 
resolved signals in the 1H NMR spectra were assigned on the 
basis of coupling constants and ge-COSY and ge-HSQC 
experiments performed on the 400 MHz spectrometer. The 
results of these experiments were processed with MestReC and 
MestreNova software. Melting points were determined on a 
melting-point apparatus and are uncorrected. Optical rotations 
were measured on a polarimeter from solutions in 1.0 dm cells 
of capacity 1.0 or 0.3 mL. Electrospray mass spectra were 
recorded on a micrOTOF spectrometer; accurate mass 
measurements were achieved by using sodium formate as an 
external reference. Copies of NMR spectra for all new 
compounds are provided in the Supporting Information.  
Preparation of (3R,3aS,5R,6R,7R,7aS,7′R,7′aS)-6,7-dibenzyloxy-
5-(benzyloxymethyl)-7′-methoxy-7′,7′a-
dimethylspiro[1,3a,5,6,7,7a-hexahydropyran[3,2-b]pyrrol-3,3′-
2H-oxazolo[4,3-b]oxazol]- 2,5′-dione 1 
Raney Ni (2.00 g) was suspended in H2O (12 mL), and 
hexachloroplatinic acid (50 mg) and sodium hydroxide 20% 
(400 μL) were added under stirring. The mixture was heated at 
50 °C. After the mixture was stirred for 2.5 h, sodium 
hydroxide 40% (6 mL) was added, keeping the stirring and the 
heating. After 1.5 h of stirring, a white cloud in the top of the 
flask appeared, which was removed by decantation; the 
resulting solution was then washed with warm water (3 × 15 
mL) and ethanol (3 × 15 mL). The catalyst obtained was 
suspended in ethanol (10 mL) and prehydrogenated for 10 min. 
An ethanol/ethyl acetate solution (5:2, 7 mL) of Michael adduct 
(200 mg, 0.28 mmol) was added, and the mixture was stirred 
under molecular hydrogen at room temperature and 
atmospheric pressure for 5 h. The crude product was filtered, 
and the liquid phase was concentrated and purified by silica gel 
column chromatography (ethyl acetate/hexane, 7:3), to afford 
compound 1 (105 mg, 0.16 mmol, 57%) as a colorless oil. 
Physical data are agree with those reported in the literature.ref 
Preparation of (3R,3aS,5R,6R,7R,7aS)-3-Amino-6,7-
bis(benzyloxy)-5-(benzyloxymethyl)-3-(hydroxymethyl)-2-oxo-
1,3a,5,6,7,7a-hexahydropyrano[3,2-b]pyrrol 2 
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Compound 1 (105 mg, 0.163 mmol) was dissolved in THF (10 
ml). A 4 M solution of HCl (3.6 mL) was then added and the 
mixture was heated up to 40 ºC for 12 h under stirring. The 
crude obtained after concentration was dissolved in absolute 
ethanol (5 mL). Propylene oxide (5 mL) was added and the 
mixture was heated to reflux for 2 h under stirring. 
Concentration and purification of the crude product by silica 
gel column chromatography (dichloromethane/methanol, 15:1) 
afforded compound 2 (60 mg, 0.116 mmol, 71%) as a 
colourless oil. [𝛼]𝐷
20 = +64.8 (c 1.0 in CHCl3). HRMS ESI+ 
(m/z) = 519.2495 [M+H]+; calculated for C30H35N2O6+ = 
519.2490. 1H NMR (400 MHz, CDCl3)  = 3.52-3.61 (m, 2H, 
H7, BnOCHaHb), 3.67 (d, 1H, J = 12.0 Hz, CHcHdOH), 3.71-
3.83 (m, 2H, CHcHdOH, BnOCHaHb), 4.03-4.15 (m, 3H, H5, 
H6, H7a), 4.24 (d, 1H, J = 4.8 Hz, H3a), 4.48-4.59 (m, 4H, 
PhCH2O, PhCHeHfO, PhCHgHhO), 4.68 (d, 1H, J = 11.6 Hz, 
PhCHeHfO, 4.84 (d, 1H, J = 11.6 Hz, PhCHgHhO), 6.84 (s, 1H, 
NH), 7.20-7.40 (m, 15H, Ph). 13C NMR (100 MHz, CDCl3)  = 
56.2 (C7a), 62.3 (C3), 65.1 (CH2OH), 67.2 (BnOCH2), 71.9 
(PhCHeHfO), 72.5 (C6), 73.6 (PhCH2O), 74.5 (PhCHgHhO), 
76.2 (C5), 76.7 (C3a), 81.3 (C7), 127.8, 127.9, 128.0, 128.3, 
128.5, 128.6, 128.8, 137.6, 137.9, 138.1 (Ph), 177.8 (CO). 
Preparation of [(3R,3aS,5R,6R,7R,7aS)-6,7-Bis(benzyloxy)-5-
(benzyloxymethyl)-2-oxo-3-palmitamido-1,3a,5,6,7,7a-
hexahydropyrano[3,2-b]pyrrol-3-yl]methyl palmitate 3 
Compound 2 (45 mg, 0.086 mmol) was dissolved in 
dichloromethane (2 mL) and palmitoyl chloride (80 L, 0.26 
mmol) was added. Et3N (50 L, 0.36 mmol) was then added 
and the mixture was stirred at room temperature for 12 h. A 0.5 
M solution of HCl (2 mL) was added. The organic layer was 
separated and the aqueous one was washed with 
dichloromethane (3 × 2 mL). The organic phases were collected 
and dried with anhydrous Na2SO4. Concentration and 
purification of the crude product by silica gel column 
chromatography (hexane/ethyl acetate, 65:35) afforded 
compound 3 (60 mg, 0.06 mmol, 70%) as a colourless oil. [𝛼]𝐷
20 
= +34.5 (c 1.0 in CHCl3). HRMS ESI+ (m/z) = 995.7071 
[M+H]+; calculated for C62H95N2O8+ = 995.7083. 1H NMR (400 
MHz, CDCl3)  = 0.88 (t, 6H, J = 6.5 Hz, CH3), 1.19-1.35 (m, 
48H, (CH2)12CH3), 1.51-1.64 (m, 4H, CH2(CH2)12CH3), 2.18 (t, 
2H, J = 7.6 Hz, NHCOCH2), 2.24 (t, 2H, J = 7.6 Hz, 
OCOCH2), 3.52-3.60 (m, 2H, H7, BnOCHaHb), 3.63-3.70 (m, 
1H, BnOCHaHb), 4.03-4.10 (m, 1H, H5), 4.11-4.15 (m, 1H, H6), 
4.29-4.36 (m, 2H, H7a, CHcHdOCO), 4.42-4.54 (m, 4H, 
CHcHdOCO, PhCH2O, PhCHeHfO), 4.58 (d, 1H, J = 11.6 Hz, 
PhCHgHhO), 4.66-4.72 (m, 2H, H3a, PhCHeHfO), 4.88 (d, 1H, J 
= 11.6 Hz, PhCHgHhO), 6.06 (NH), 6.32 (NH), 7.22-7.40 (m, 
15H, Ph). 13C NMR (100 MHz, CDCl3)  = 14.2 (CH3), 22.8, 
24.9, 25.3, 29.3, 29.5, 29.6, 29.7, 29.8, 32.1 ((CH2)13CH3), 34.2 
(OCOCH2), 36.2 (NHCOCH2), 53.5 (C3), 56.0 (C7a), 63.1 
(CH2OCO), 67.8 (BnOCH2), 71.5 (PhCHeHfO), 71.7 (C6), 73.6 
(PhCH2O), 74.4 (PhCHgHhO), 75.9 (C3a), 76.5 (C5), 81.4 (C7), 
127.7, 127.8, 127.9, 128.2, 128.4, 128.6, 128.8, 137.6, 138.1, 
138.4 (Ph), 172.4 (OCO), 173.2 (NHCO), 173.7 (NHCO). 
Preparation of [(3R,3aS,5R,6R,7R,7aR)-6,7-Dihydroxy-5-
(hydroxymethyl)-2-oxo-3-palmitamido-1,3a,5,6,7,7a-
hexahydropyrano[3,2-b]pyrrol-3-yl]methyl palmitate 4 
A hydrogenolysis of a methanol solution (5 mL) of the 
compound 3 (37 mg, 0.037 mmol) was held under ambient 
pressure and temperature, using Pd-C (35 mg) and HCl conc. (3 
drops) as catalyst. The reaction was performed for 12 h and the 
catalyst was filtered over diatomaceous earth. The liquid phase 
was concentred affording compound 4 (25 mg, 0,034 mmol, 
93%) as a yellow oil. [𝛼]𝐷
20 = +20.6 (c 0.99 in methanol). 
HRMS ESI+ (m/z) = 725.5669 [M+H]+; calculated for 
C41H77N2O8+ = 725.5674. 1H NMR (400 MHz, CD3OD)  = 
0.89 (t, 6H, J = 6.5 Hz, CH3), 1.24-1.35 (m, 48H, (CH2)12CH3), 
1.54-1.67 (m, 4H, CH2(CH2)12CH3), 2.23 (t, 2H, J = 6.7 Hz, 
NHCOCH2), 2.36 (t, 2H, J = 7.3 Hz, OCOCH2), 3.70-3.78 (m, 
3H, CH2OH, H7), 3.79-3.85 (m,1H, H5), 3.91-4.02 (m, 2H, H6, 
H7a), 4.31 (d, 1H, J = 10.7 Hz, CHaHbOCO), 4.45-4.52 (m, 1H, 
CHaHbOCO), 4.83 (m, 1H, H3a). 13C NMR (100 MHz, CD3OD) 
 = 14.4 (CH3), 23.7, 25.8, 26.8, 30.2, 30.4, 30.5, 30.6, 30.7, 
30.8, 33.0 ((CH2)13CH3), 34.9 (OCOCH2), 36.7 (NHCOCH2), 
56.9 (C7a), 61.6 (CH2OH), 62.6 (CH2OCO), 63.1 (C3), 69.4 
(C6), 73.3 (C7), 76.0 (C3a), 78.8 (C5), 174.7 (OCO), 175.7 
(NHCO), 176.0 (NHCO). 
Preparation of N-[(3R,3aS,5R,6R,7R,7aS)-6,7-Bis(benzyloxy)-5-
(benzyloxymethyl)-3-hydroxymethyl-2-oxo -1,3a,5,6,7,7a-
hexahydropyrano[3,2-b]pyrrol-3-yl]palmitamide 5 
A methanol solution of sodium methoxide 0.5 M (2 mL) was 
added to a methanol solution (4 mL) of the compound 3 (76 
mg, 0.076 mmol). The mixture was stirred for 1 h and sulfonic 
acid resine Dowex® was then added. The liquid phase was 
filtered, concentrated and the residue was purified by silica gel 
column chromatography (hexane/ethyl acetate, 15:85) to afford 
compound 5 (40 mg, 0.053 mmol, 70%) as a colourless oil. 
[𝛼]𝐷
20 = +66.0 (c 1.0 in CHCl3). HRMS ESI+ (m/z) = 757.4788 
[M+H]+; calculated for C46H65N2O7+ = 757.4786. 1H NMR (400 
MHz, CDCl3)  = 0.88 (t, 3H, J = 6.7 Hz, CH3), 1.22-1.33 (m, 
24H, (CH2)12CH3), 1.55-1.65 (m, 2H, CH2(CH2)12CH3), 2.20 (t, 
2H, J = 7.6 Hz, NHCOCH2), 3.48 (dd, 1H, J = 10.3, 4.7 Hz, 
BnOCHaHb), 3.56 (d, 1H, J = 8.1 Hz, H7) , 3.67-3.75 (m, 2H, 
BnOCHaHb, CHcHdOH), 3.98 (d, 1H, J = 12.0 Hz, CHcHdOH), 
4.09 (d, 1H, J = 4.9 Hz, H6), 4.11-4.18 (m, 1H, H5), 4.38 (t, 1H, 
J = 7.2 Hz, H7a), 4.47 (d, 1H, J =11.9 Hz, PhCHeHfO), 4.49 (s, 
2H, PhCH2O), 4.55 (d, 1H, J = 11.8 Hz, PhCHgHhO), 4.61 (d, 
1H, J = 6.3, H3a) 4.68 (d, 1H, J = 11.8 Hz, PhCHeHfO), 4.87 (d, 
1H, J = 11.8 Hz, PhCHgHhO), 6.22 (NH), 6.56 (NH), 7.20-7.39 
(m, 15H, Ph). 13C NMR (100 MHz, CDCl3)  = 14.1 (CH3), 
22.7, 25.3, 29.2, 29.4, 29.5, 29.7, 32.0 ((CH2)13CH3), 35.8 
(NHCOCH2), 56.3 (C7a), 63.5 (C3), 64.0 (CH2OH), 67.4 
(BnOCH2), 71.5 (C6), 71.6 (PhCHeHfO), 73.5 (PhCH2O), 74.2 
(PhCHgHhO), 76.7 (C5, C3a), 81.4 (C7), 127.6, 127.8, 127.9, 
128.2, 128.4, 128.5, 128.7, 137.5, 137.8, 138.0 (Ph), 173.5 
(NHCO), 173.9 (NHCO). 
Preparation of N-[(3R,3aS,5R,6R,7R,7aR)-6,7-Dihydroxy-3,5-
bis(hydroxymethyl)-2-oxo -1,3a,5,6,7,7a-hexahydropyrano[3,2-
b]pyrrol-3-yl]palmitamide 6 
A hydrogenolysis of a methanol solution (5 mL) of the 
compound 5 (35 mg, 0.046 mmol) was held under ambient 
pressure and temperature, using Pd-C (35 mg) and HCl conc. (3 
drops) as catalyst. The reaction was performed for 12 h and the 
catalyst was filtered over diatomaceous earth. The liquid phase 
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was concentred affording compound 6 (22 mg, 0,045 mmol, 
98%) as a yellow oil. [𝛼]𝐷
20 = +15.1 (c 1.0 in methanol). HRMS 
ESI+ (m/z) = 487.3386 [M+H]+; calculated for C25H47N2O7+ = 
487.3378. 1H NMR (400 MHz, CD3OD)  = 0.83 (t, 3H, J = 5.8 
Hz, CH3), 1.13-1.36 (m, 24H, (CH2)12CH3), 1.49-1.62 (m, 2H, 
CH2(CH2)12CH3), 2.38 (t, 2H, J = 6.7 Hz, NHCOCH2), 3.65-
4.02 (m, 6H, CH2OH, H5, H6, H7, H7a), 4.39 (d, 1H, J = 11.3 
Hz, C3CHaHbOH), 4.48 (d, 1H, J = 11.7 Hz, C3CHaHbOH), 
4.74 (d, 1H, J = 5.3 Hz, H3a). 13C NMR (100 MHz, CD3OD)  
= 14.3 (CH3), 23.5, 25.5, 30.0, 30.3, 30.4, 30.5, 30.6, 32.9 
((CH2)13CH3), 34.4 (NHCOCH2), 55.8 (C7a), 61.6 (C3CH2OH), 
61.9 (CH2OH), 63.0 (C3), 69.2 (C6), 73.3 (C7), 74.6 (C3a), 79.0 
(C5), 174.1 (2 NHCO). 
Preparation of [(3R,3aS,5R,6R,7R,7aS)-3-Amino-6,7-
bis(benzyloxy)-5-(benzyloxymethyl)-2-oxo-1,3a,5,6,7,7a-
hexahydropyrano[3,2-b]pyrrol-3-yl]methyl palmitate 7 
Compound 1 (82 mg, 0.127 mmol) was dissolved in THF (8 
mL). A 4 M solution of HCl (2.8 mL) was then added and the 
mixture was heated up to 40 ºC for 12 h under stirring. The 
crude obtained after concentration was dissolved in TFA (4 
mL) and palmitoyl chloride was added (385 L, 1.27 mmol). 
The mixture was stirred at room temperature for 15 min and 
absolute ethanol (10 mL) was added to quench the reaction. 
After concentration, the crude was dissolved in absolute ethanol 
(5 mL). Propylene oxide (5 mL) was added and the mixture was 
heated to reflux for 2 h under stirring. Concentration and 
purification of the crude product by silica gel column 
chromatography (hexane/ethyl acetate, 65:35) afforded 
compound 7 (64 mg, 0.085 mmol, 67%) as a colourless oil. 
[𝛼]𝐷
20 = +52.9 (c 1.0 in CHCl3). HRMS ESI+ (m/z) = 757.4788 
[M+H]+; calculated for C46H65N2O7+ = 757.4786. 1H NMR (400 
MHz, CDCl3)  = 0.88 (t, 3H, J = 6.7 Hz, CH3), 1.20-1.36 (m, 
24H, (CH2)12CH3), 1.54-1.64 (m, 2H, CH2(CH2)12CH3), 2.27 (t, 
2H, J = 7.8 Hz, OCOCH2), 3.55 (d, 1H, J = 5.3 Hz, H7), 3.70 
(d, 1H, J = 5.2 Hz, BnOCH2) , 4.05-4.12 (m, 2H, H3a, H5), 4.14-
4.20 (m, 2H, H7a, H6), 4.47 (d, 1H, J = 2.7 Hz, CH2OCO), 4.49-
4.61 (m, 4H, PhCHaHbO, PhCHcHdO, PhCH2O), 4.69 (d, 1H, J 
= 11.8 Hz, PhCHaHbO), 4.81 (d, 1H, J = 11.5 Hz, PhCHcHdO), 
6.57 (NH), 7.24-7.38 (m, 15H, Ph). 13C NMR (100 MHz, 
CDCl3)  = 14.2 (CH3), 22.8, 26.1, 29.3, 29.5, 29.6, 29.7, 29.8, 
32.0 ((CH2)13CH3), 28.2 (NHCOCH2), 57.3 (C7a), 67.2 
(BnOCH2), 68.3 (CH2OCO), 72.0 (PhCHaHbO), 73.0 (C3a), 73.5 
(PhCH2O), 74.2 (PhCHcHdO), 74.6 (C6), 76.2 (C5), 78.7 (C3), 
80.1 (C7), 127.8, 127.9, 128.2, 128.5, 128.6, 128.7, 137.7, 
138.1, 138.2 (Ph), 170.9 (OCO), 175.5 (NHCO). 
Preparation of [(3R,3aS,5R,6R,7R,7aR)-3-Amino-6,7-
bis(hydroxy)-5-(hydroxymethyl)-2-oxo-1,3a,5,6,7,7a-
hexahydropyrano[3,2-b]pyrrol-3-yl]methyl palmitate 8 
A hydrogenolysis of a methanol solution (5 mL) of the 
compound 7 (50 mg, 0.065 mmol) was held under ambient 
pressure and temperature, using Pd-C (50 mg) and HCl conc. (3 
drops) as catalyst. The reaction was performed for 12 h and the 
catalyst was filtered over diatomaceous earth. The liquid phase 
was concentred affording compound 8 (30 mg, 0,062 mmol, 94 
%) as a yellow oil. [𝛼]𝐷
20 = -3.9 (c 1.0 in methanol). HRMS 
ESI+ (m/z) = 487.3388 [M+H]+; calculated for C25H47N2O7+ = 
487.3378. 1H NMR (400 MHz, CD3OD)  = 0.89 (t, 3H, J = 6.4 
Hz, CH3), 1.22-1.39 (m, 24H, (CH2)12CH3), 1.58-1.67 (m, 2H, 
CH2(CH2)12CH3), 2.43 (t, 2H, J = 7.4 Hz, OCOCH2), 3.70-3.78 
(m, 3H, CH2OH, H7), 3.79-3.85 (m, 1H, H5), 3.93 (t, 1H, J = 
7.6 Hz, H7a), 3.99 (s, 1H, H6), 4.44 (d, 1H, J = 12.1 Hz, 
CHaHbOCO), 4.53 (d, 1H, J = 11.9 Hz, CHaHbOCO), 4.77 (d, 
1H, J = 7.2 Hz, H3a). 13C NMR (100 MHz, CD3OD)  = 14.4 
(CH3), 23.7, 25.7, 30.1, 30.4, 30.6, 30.7, 30.8, 33.0 
((CH2)13CH3), 34.5 (OCOCH2), 55.9 (C7a), 61.7 (CH2OCO), 
62.0 (CH2OH), 63.1 (C3), 69.3 (C6), 73.5 (C7), 74.8 (C3a), 79.2 
(C5), 170.3 (OCO), 174.1 (NHCO). 
Preparation of [(3R,3aS,5R,6R,7R,7aS)-3-Acetamido-6,7-
bis(benzyloxy)-5-(benzyloxymethyl)-2-oxo-1,3a,5,6,7,7a-
hexahydropyrano[3,2-b]pyrrol-3-yl]methyl palmitate 10 
Compound 9 (60 mg, 0.107 mmol) was dissolved in 
dichloromethane (2 mL) and palmitoyl chloride (70 L, 0.23 
mmol) was added. Et3N (44 L, 0.32 mmol) was then added 
and the mixture was stirred at room temperature for 12 h. A 0.5 
M solution of HCl (2 mL) was added. The organic layer was 
separated and the aqueous one was washed with 
dichloromethane (3 × 2 mL). The organic phases were collected 
and dried with anhydrous Na2SO4. Concentration and 
purification of the crude product by silica gel column 
chromatography (hexane/ethyl acetate, 35:65) afforded 
compound 10 (63 mg, 0.079 mmol, 74%) as a colourless oil. 
[𝛼]𝐷
20 = +41.0 (c 1.0 in CHCl3). HRMS ESI+ (m/z) = 799.4853 
[M+H]+; calculated for C48H67N2O8+ = 799.4892. 1H NMR (400 
MHz, CDCl3)  = 0.88 (t, 3H, J = 6.7 Hz, CH3), 1.21-1.30 (m, 
24H, (CH2)12CH3), 1.51-1.58 (m, 2H, CH2(CH2)12CH3), 1.98 (s, 
3H, NHAc), 2.23 (t, 2H, J = 7.5 Hz, OCOCH2), 3.53-3.59 (m, 
2H, BnOCHaHb, H7), 3.66 (dd, 1H, J = 9.5, 6.9 Hz, 
BnOCHaHb), 4.07 (dd, 1H, J = 11.1, 6.3 Hz, H5), 4.13 (d, 1H, J 
= 4.2 Hz, H6), 4.27-4.34 (m, 2H, H7a, CHcHdOCO), 4.42-4.52 
(m, 4H, CHcHdOCO, PhCH2O, PhCHeHfO), 4.58 (d, 1H, J = 
11.6, PhCHgHhO), 4.66-4.72 (m, 2H, PhCHeHfO, H3a), 4.87 (d, 
1H, J = 11.6 Hz, PhCHgHhO), 6.07-6.18 (m, 1H, NHAc), 6.38 
(s, 1H, NHCO), 7.22-7.40 (m, 15H, Ph). 13C NMR (100 MHz, 
CDCl3)  = 14.1 (CH3), 23.1 (NHCOCH3), 22.7, 24.8, 29.2, 
29.3, 29.4, 29.5, 29.7, 31.9, 34.1 (CO(CH2)14CH3), 55.9 (C7a), 
63.0 (CH2OCO), 63.2 (C3) 67.7 (BnOCH2), 71.4 (PhCHeHfO), 
71.6 (C6), 73.5 (PhCH2O), 74.3 (PhCHgHhO), 75.7 (C3a), 76.4 
(C5), 81.2 (C7), 127.7, 127.8, 127.9, 128.2, 128.3, 128.5, 128.7, 
137.5, 138.0, 138.2 (Ph), 170.0 (OCO), 172.3 (NHCOCH3), 
173.6 (NHCO). 
Preparation of [(3R,3aS,5R,6R,7R,7aR)-3-Acetamido-6,7-
bis(hydroxy)-5-(hydroxymethyl)-2-oxo-1,3a,5,6,7,7a-
hexahydropyrano[3,2-b]pyrrol-3-yl]methyl palmitate 11 
A hydrogenolysis of a methanol solution (5 mL) of the 
compound 10 (63 mg, 0.079 mmol) is held under ambient 
pressure and temperature, using Pd-C (60 mg) and HCl conc. (3 
drops) as catalyst. The reaction is performed for 12 h and the 
catalyst is filtered over diatomaceous earth. The liquid phase is 
concentred affording the compound 11 (35 mg, 0,066 mmol, 84 
%) as a yellow oil. [𝛼]𝐷
20 = +22.7 (c 1.0 in H2O). HRMS ESI+ 
(m/z) = 529.3493 [M+H]+; calculated for C27H49N2O8+ = 
529.3483. 1H NMR (400 MHz, CD3OD)  = 0.88 (t, 3H, J = 6.4 
Hz, CH3), 1.19-1.37 (m, 24H, (CH2)12CH3), 1.53-1.66 (m, 2H, 
CH2(CH2)12CH3), 2.26-2.39 (m, 2H, OCOCH2), 3.68-4.03 (m, 
6H, CH2OH, H5, H6, H7, H7a), 4.25-4.35 (m, 1H, CHaHbOCO), 
4.46-4.54 (m, 1H, CHaHbOCO), 4.83 (m, 1H, H3a). 13C NMR 
(100 MHz, CD3OD)  = 14.3 (CH3), 23.6, 25.8, 25.9, 30.1, 
30.2, 30.3, 30.4, 30.5, 30.6, 30.7, 32.9 ((CH2)13CH3), 34.7 
(OCOCH2), 56.9 (C7a), 61.6 (CH2OH), 62.2 (CH2OCO), 64.9 
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(C3), 69.3 (C6), 73.1 (C7), 75.9 (C3a), 78.7 (C5), 171.4 (OCO), 
174.6 (NHCO), 176.0 (NHCO). 
 
Preparation of [(3R,3aS,5R,6R,7R,7aS)-3-Amino-6,7-
bis(benzyloxy)-5-(benzyloxymethyl)-2-oxo-1,3a,5,6,7,7a-
hexahydropyrano[3,2-b]pyrrol-3-yl]methyl acetate 12 
Compound 1 (73 mg, 0.113 mmol) was dissolved in THF (7 
mL). A 4 M solution of HCl (2.5 mL) was then added and the 
mixture was heated up to 40 ºC for 12 h under stirring. The 
crude obtained after concentration was dissolved in TFA (4 
mL) and acetyl chloride was added (80 L, 1.13 mmol). The 
mixture was stirred at room temperature for 15 min and 
absolute ethanol (10 mL) was added to quench the reaction. 
After concentration, the crude was dissolved in absolute ethanol 
(5 mL). Propylene oxide (5 mL) was added and the mixture was 
heated to reflux for 2 h under stirring. Concentration and 
purification of the crude product by silica gel column 
chromatography using ethyl acetate as eluent afforded 
compound 12 (27 mg, 0.048 mmol, 42%) as a colourless oil. 
[𝛼]𝐷
20 = +76.7 (c 1.0 in CHCl3). HRMS ESI+ (m/z) = 561.2590 
[M+H]+; calculated for C32H37N2O7+ = 561.2595. 1H NMR (400 
MHz, CDCl3)  = 1.99 (s, 3H, CH3), 3.54 (s, 1H, H7), 3.67-3.73 
(m, 2H, BnOCH2), 4.06-4.12 (m, 2H, H3a, H5), 4.15-4.20 (m, 
2H, H6, H7a), 4.41-4.49 (m, 2H, CH2OAc), 4.49-4.61 (m, 4H, 
PhCHaHbO, PhCHcHdO, PhCH2O), 4.70 (d, 1H, J = 11.8 Hz, 
PhCHaHbO), 4.82 (d, 1H, J = 11.4 Hz, PhCHcHdO), 6.51 (s, 1H, 
NH), 7.24-7.39 (m, 15H, Ph). 13C NMR (100 MHz, CDCl3)  = 
14.0 (CH3), 57.4 (C7a), 67.2 (BnOCH2), 68.6 (CH2OAc), 71.9 
(PhCHaHbO), 72.9 (C3a), 73.5 (PhCH2O), 74.3 (PhCHcHdO), 
74.6 (C6), 76.2 (C5), 78.8 (C3), 80.2 (C7), 127.8, 127.9, 128.3, 
128.5, 128.6, 128.8, 137.7, 138.1, 138.2 (Ph), 167.8 (COCH3), 
175.5 (NHCO). 
Preparation of [(3R,3aS,5R,6R,7R,7aR)-3-Amino-6,7-
bis(hydroxy)-5-(hydroxymethyl)-2-oxo-1,3a,5,6,7,7a-
hexahydropyrano[3,2-b]pyrrol-3-yl]methyl acetate 13 
A hydrogenolysis of a methanol solution (5 mL) of the 
compound 12 (27 mg, 0.048 mmol) was held under ambient 
pressure and temperature, using Pd-C (25 mg) and HCl conc. (3 
drops) as catalyst. The reaction was performed for 12 h, the 
catalyst was then filtered over diatomaceous earth and the 
liquid phase is concentred. The residue was dissolved in H2O (5 
mL) and extracted with ethyl acetate (2 × 5 mL). The combined 
aqueous phases were concentrated and the residue was 
dissolved in H2O (2 mL) and eluted through a reverse-phase 
Sep-pak C18 cartridge affording, after evaporation of water, 
compound 13 (13 mg, 0,044 mmol, 94%) as a yellow oil. [𝛼]𝐷
20 
= +42.3 (c 1.0 in H2O). HRMS ESI+ (m/z) = 291.1188 [M+H]+; 
calculated for C11H19N2O7+ = 291.1187. 1H NMR (400 MHz, 
D2O)  = 2.17 (s, 3H, CH3), 3.69-3.84 (m, 2H, CH2OH), 3.84-
4.08 (m, 4H, H5, H6, H7, H7a), 4.51 (d, 1H, J = 12.3 Hz, 
CHaHbOAc),  4.66 (d, 1H, J = 12.3 Hz, CHaHbOAc), 4.96 (d, 
1H, J = 8.1 Hz, H3a). 13C NMR (100 MHz, D2O)  = 20.1 
(CH3), 53.1 (C7a), 61.1 (CH2OAc), 61.4 (CH2OH), 61.8 (C3), 
67.4 (C6), 71.8 (C7), 74.3 (C3a), 77.4 (C5), 169.7 (COAc), 172.6 
(NHCO). 
Preparation of (3R,3aS,5R,6R,7R,7aR)-3-Amino-6,7-dihydroxy-
3,5-bis(hydroxymethyl)- 1,3a,5,6,7,7a-hexahydropyrano[3,2-
b]pyrrol-2-one 14 
A hydrogenolysis of a methanol solution (5 mL) of the 
compound 2 (35 mg, 0.067 mmol) was held under ambient 
pressure and temperature, using Pd-C (35 mg) and HCl conc. (3 
drops) as catalyst. The reaction was performed for 12 h, the 
catalyst was then filtered over diatomaceous earth and the 
liquid phase was concentred. The residue was dissolved in H2O 
(5 mL) and extracted with ethyl acetate (2 × 5 mL). The 
combined aqueous phases were concentrated affording 
compound 14 (16 mg, 0,064 mmol, 96 %) as a yellow oil. [𝛼]𝐷
20 
= +32.6 (c 1.0 in H2O). HRMS ESI+ (m/z) = 249.1087 [M+H]+; 
calculated for C9H17N2O6+ = 249.1081. 1H NMR (400 MHz, 
D2O)  = 3.71-3.84 (m, 2H, CH2OH), 3.90-4.16 (m, 6H, H5, H6, 
H7, H7a, C3CH2OH), 4.96 (d, 1H, J = 5.6 Hz, H3a). 13C NMR 
(100 MHz, D2O)  = 53.0 (C7a), 59.0 (C3CH2OH), 61.4 
(CH2OH), 63.6 (C3), 67.4 (C6), 71.8 (C7), 73.8 (C3a), 77.3 (C5), 
170.7 (NHCO).  
Inhibition Studies with Commercial Enzymes. Inhibition 
constant (Ki) values were determined by spectrophotometrically 
measuring the residual hydrolytic activities of the glycosidases 
against the respective p-nitrophenyl α- or β-D-glycopyranoside, 
or o-nitrophenyl β-D-galactopyranoside (for β-galactosidases), 
in the presence of compounds 4, 6, 8, 11, 13, 14 and 15. Each 
essay was performed in phosphate buffer at the optimal pH of 
each enzyme. The reactions were initiated by addition of 
enzyme to a solution of the substrate in the absence or presence 
of various concentrations of inhibitor. The mixture was 
incubated for 10-30 min at 37 °C, and the reaction was 
quenched by addition of 1 M Na2CO3. Reaction times were 
appropiate to obtain 10−20% conversion of the substrate in 
order to achieve linear rates. The absorbance of the resulting 
mixture was determined at 405. Approximate values of Ki were 
determined using a fixed concentration of substrate (around the 
Km value for the different glycosidases) and various 
concentrations of inhibitor. Full Ki determinations and enzyme 
inhibition mode were determined from the slope of Lineweaver
−Burk plots and double reciprocal analysis. 
Lysosomal enzyme activity assay. Lysosomal enzyme 
activities in cell lysates were determined as described 
previously.26 Briefly, cells were scraped in ice-cold 0.1% Triton 
X-100 in water. After centrifugation (6,000 rpm for 15 min at 4 
ºC) to remove insoluble materials, protein concentrations were 
determined using Protein Assay Rapid Kit (Wako, Tokyo, 
Japan). The lysates were incubated at 37 ºC with the 
corresponding 4-methylumbelliferyl -D-glycopyranoside 
solution in 0.1 M citrate buffer (pH 4). The librated 4-
methylumbelliferone was measured with a fluorescence plate 
reader (exitation 340 nm; emission 460 nm; Infinite F500, 
TECAN Japan, Kawasaki, Japan). For enzyme inhibition assay, 
cell lysates from normal skin fibroblasts were mixed with the 4-
methylumbelliferyl -D-glycopyranoside substrates in the 
absence or presence of increasing concentrations of the tested 
derivatives. 
Cell culture and GCase activity enhancement assay. Human 
skin fibroblasts from a healthy and three Gaucher disease 
patients (with N370S/ N370S, F213I/ F213I and L444P/L444P 
mutations) were maintained in our laboratory with DMEM 
supplemented with 10% FBS as the culture medium. For 
enzyme activity enhancement assay, cells were cultured in the 
presence of different concentrations of the candidates or DMSO 
alone (as a control) for 5 days and harvested by scraping.26 
Cytotoxicity of the compounds was monitored by measuring 
the lactate dehydrogenase activities in the cultured supernatants 
(LDH assay kit, Wako, Tokyo, Japan). 
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Unrestrained Molecular Dynamics Simulations. All 
molecular dynamics simulations were carried out on the Finis-
Terrae cluster of the Centro de Supercomputación de Galicia 
(CESGA), Spain. Starting geometries for complexes were 
generated from the available data deposited in the Protein Data 
Bank (pdb code: 1JYN for -galactosidase) and modified 
accordingly. Each model complex was immersed in a 10 Å-
sided cube with pre-equilibrated TIP3P water molecules. To 
equilibrate the system, we followed a protocol consisting of 10 
steps. Firstly, only the water molecules are minimized, and then 
heated to 300 K. The water box, together with Na+ ions, was 
then minimized, followed by a short MD simulation. At this 
point, the system was minimized in the four following steps 
with positional restraints imposed on the solute, decreasing the 
force constant step by step from 20 to 5 kcal·mol−1. Finally, a 
non-restraint minimization was performed. The production 
dynamics simulations were accomplished at a constant 
temperature of 300 K (by applying the Berendsen coupling 
algorithm for the temperature scaling) and constant pressure (1 
bar). Particle Mesh Ewald Method, to introduce long-range 
electrostatic effects, and periodic boundary conditions were 
also used. SHAKE algorithm for hydrogen atoms, which allows 
using a 2 fs time step, was also employed. Finally, a 9Å cutoff 
was applied for the Lennard-Jones interactions. MD simulations 
were performed with the sander module of AMBER 11.0 
(parm99 force field), which was implemented with GAFF 
parameters27to accurately simulate the corresponding ligands. A 
simulation length of 100 ns and the trajectory coordinates were 
saved each 0.5 ps. 
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